Skip to content

Study · Randomized controlled trial · 2025

8 results

Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.

Pearson ER, Del Prato S, Pavo I, Franco DR, Zheng J, Nicolay C, Hemmingway A, Wiese RJ, Kahn SE

Diabetes1 Oct 2025Cited by 6 (Europe PMC)

PMID40633089 (opens in a new tab)PMCIDPMC12451090 (opens in a new tab)DOI10.2337/db25-0276 (opens in a new tab)PepBankPUB-40633089
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes and increased cardiovascular risk, 75-84% of tirzepatide-treated participants who reached HbA1c of 48 mmol/mol (6.5%) or lower at 52 weeks sustained it until study end.

    In plain wordsIn type 2 diabetes, 75% to 84% of tirzepatide users who reached an HbA1c of 6.5% at 52 weeks kept it until study end.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSustained HbA1c of 48 mmol/mol (6.5%) or lower
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · median 81 weeksAs given in this study (human).

    Measurements

    Participants sustaining HbA1c of 48 mmol/mol or lower
    75 to 84%
    tirzepatide, until study end

    Source sentences

    Summary
    For tirzepatide-treated participants achieving HbA1c ≤48 mmol/mol (6.5%) at 52 weeks, 75-84% sustained this until study end (median 81 weeks).
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes and increased cardiovascular risk, 79-82% of participants who achieved weight loss of 10% or more at 52 weeks maintained it.

    In plain wordsIn type 2 diabetes, 79% to 82% of tirzepatide users who lost at least 10% of weight by 52 weeks kept it off.

    Peptide
    Tirzepatide
    Outcome
    Not applicableMaintained weight loss of 10% or more
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Participants maintaining weight loss of 10% or more
    79 to 82%
    tirzepatide

    Source sentences

    Summary
    For participants achieving ≥10% weight loss at 52 weeks, 79-82% maintained weight loss.
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes treated with tirzepatide, shorter diabetes duration, lower baseline HbA1c, higher HOMA-B, metformin alone and no albuminuria at baseline predicted achieving HbA1c of 48 mmol/mol or lower.

    In plain wordsIn people with type 2 diabetes on tirzepatide, shorter diabetes duration and lower starting HbA1c, among other factors, predicted reaching an HbA1c of 6.5%.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePredictors of achieving HbA1c of 48 mmol/mol or lower at 52 weeks
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Factors predicting achievement were higher tirzepatide dose, shorter diabetes duration, and lower HbA1c, higher HOMA of β-cell function (HOMA-B), metformin alone, and absence of albuminuria at baseline.
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes, a higher tirzepatide dose predicted achieving HbA1c of 48 mmol/mol or lower at 52 weeks.

    In plain wordsIn people with type 2 diabetes, a higher tirzepatide dose predicted reaching an HbA1c of 6.5% at 52 weeks.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTirzepatide dose as predictor of achieving HbA1c of 48 mmol/mol or lower
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Factors predicting achievement were higher tirzepatide dose, shorter diabetes duration, and lower HbA1c, higher HOMA of β-cell function (HOMA-B), metformin alone, and absence of albuminuria at baseline.
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes treated with tirzepatide, greater weight loss, smaller fasting glucose decrease, no sulfonylurea and higher HOMA-B at 52 weeks predicted sustained glycemic control.

    In plain wordsIn people with type 2 diabetes on tirzepatide, more weight loss and better beta-cell function predicted lasting blood sugar control, among other factors.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePredictors of sustained glycemic control
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Factors predicting sustained glycemic control were greater weight loss, smaller fasting glucose decrease, no sulfonylurea, and higher HOMA-B at 52 weeks.
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes treated with tirzepatide, female sex, no cardiovascular disease history, and lower baseline HbA1c, eGFR and triglycerides predicted achieving weight loss of 10% or more.

    In plain wordsIn people with type 2 diabetes on tirzepatide, being female and having lower starting HbA1c, among other factors, predicted losing at least 10% of weight.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePredictors of achieving weight loss of 10% or more at 52 weeks
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Factors predicting achievement were higher tirzepatide dose, female sex, no cardiovascular disease history, and lower baseline HbA1c, estimated glomerular filtration rate, and triglycerides.
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes, a higher tirzepatide dose predicted achieving weight loss of 10% or more at 52 weeks.

    In plain wordsIn people with type 2 diabetes, a higher tirzepatide dose predicted losing at least 10% of weight at 52 weeks.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTirzepatide dose as predictor of achieving weight loss of 10% or more
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Factors predicting achievement were higher tirzepatide dose, female sex, no cardiovascular disease history, and lower baseline HbA1c, estimated glomerular filtration rate, and triglycerides.
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes treated with tirzepatide, a greater decrease in LDL-cholesterol to 52 weeks predicted maintained weight loss.

    In plain wordsIn people with type 2 diabetes on tirzepatide, a bigger drop in LDL cholesterol by 52 weeks predicted keeping the weight off.

    Peptide
    Tirzepatide
    Outcome
    Not applicableLDL-cholesterol decrease as predictor of maintained weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Greater decrease in LDL-cholesterol to 52 weeks predicted maintained weight loss.
    1 context sentence
    Summary · context
    This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.